-
A completely synthetic, once-monthly, erythropoiesis-stimulating agent has been approved for the treatment of anemia in dialysis patients.
-
Managing chronic pain is a challenge for patients and clinicians alike, with 52% of chronic pain patients being treated solely by their primary care physician.1 Chronic myofascial pain affects 116 million American adults, which is more than heart disease, cancer, and diabetes combined.2
-
Medically self-sabotaging behavior encompasses a number of diverse phenomena that include factitious disorder, making medical situations worse on purpose, and preventing wounds from healing.
-
A new androgen receptor antagonist has been approved for the treatment of late-stage prostate cancer. Enzalutamide was approved 3 months ahead of schedule due to a priority review by the FDA. The drug is comarketed by Astellas Pharma and Medivation as Xtandi.
-
After careful evaluation of all the published studies regarding the possible adverse effects of statin therapy, Jukema et al have concluded that there is no proven increased risk of cognitive decline or cancer development. However, there is a possible small increased risk for the development of type 2 diabetes mellitus.
-
Beta-Blocker Use in Situations Other than Just Post-MI; Long-Term Sexual and Psychological Adverse Effects of Finasteride; Novel CV Risk Markers: How Much Cluck for the Buck?
-
Dementia and benzodiazepines; effectiveness of omega-3 fatty acid and Ginkgo biloba supplements; and FDA actions.
-
Biomarkers in the cerebrospinal fluid open the possibility of diagnosing early or even presymptomatic cases of Alzheimer's disease, thereby expanding the potential window for therapy.
-
The ECG shown above was obtained from a 22-year-old man in a wheelchair. How would you interpret the tracing? Can you think of a condition that might account for this clinical scenario?
-
The authors concluded that interruption of warfarin therapy in non-valvular atrial fibrillation patients increased the short-term risk of death or thromboembolism, especially during the first 90 days of treatment interruption.
